Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
-
EDMONTON, Alberta, March 31, 2026 (GLOBE NEWSWIRE) -- When you sit down for a routine dental visit, your oral health professional is doing more than checking your teeth. They are also examining the...
-
Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its...
-
Presentation of the molecular structure, discovery, and preclinical data supporting the potential best-in-class profile of PARG inhibitor FORX-428.
-
The Io Therapeutics, Inc. clinical stage anti-cancer RXR agonist compound demonstrated efficacy in models of human multiple myeloma.
-
EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of...
-
John Snow Labs recognized for its groundbreaking framework for automating oncology data abstraction at PHUSE US Connect 2026.
-
New oncologist formulated supplement systems aim to simplify wellness while addressing safety, dosing, and formulation challenges many survivors face.
-
The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases.
-
SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...